Cancer Immunology and Immunotherapy
A section of Cancers (ISSN 2072-6694).
Section Information
Cancer remains a leading cause of death in Western countries, and treatment of advanced stages of the disease is still limited. Discoveries in the field of cancer immunology and progress in immunotherapy as the first line therapy bring the most exciting times for delivering a potential cure for advanced cancer. Understanding the common mechanisms of tumorigenesis, including changes in tumor microenvironment, immune evasion, and antitumor immune responses, is pivotal for further development of novel therapeutics.
Following early discoveries of connection of autoimmune diseases with cancer, recent advances in T cell biology have revolutionized cancer therapy. Most importantly, standard-of-care chemotherapy and radiation effects have also been linked to immune cell-mediated anticancer effects.
Importantly, multiple clinical trials using checkpoint blockade agents, ATC transfer therapies, and cancer vaccines show much better outcomes than the most effective chemotherapeutic agents.
The aim of this Special Section is to publish findings that relate to cancer immunology and therapies based on the immune-targeting. Topics include, but are not limited to:
- checkpoint blockade
- innate immunity
- adaptive responses
- vaccines
- ATC transfer therapy
- immune evasion
- immune switch
- immunosuppression
- tumor microenvironment
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- Targeting the Tumor Microenvironment in Blood Cancer (Deadline: 30 November 2024)
- New Insights of Hematology in Cancer (Deadline: 30 November 2024)
- Quantitative Image Tissue Analysis Based on Multiplexed Platforms for Immuno-Oncology Applications (Deadline: 30 November 2024)
- State-of-the-Art Research on Multiple Myeloma Progression (Deadline: 30 November 2024)
- Innovative Immunotherapies: CAR-T Cell Therapy for Cancers (Deadline: 13 December 2024)
- The Role of Immunotherapy in Hematological Malignancies Volume II (Deadline: 15 December 2024)
- Immunotherapy in Non-Small Cell Lung Cancers (Deadline: 22 December 2024)
- Research on Cell Death in Cancer Immunotherapy (Deadline: 25 December 2024)
- Cancer Immunotherapy in Clinical and Translational Research (Deadline: 31 December 2024)
- Immune Checkpoint Inhibitors for Urologic Cancers (Deadline: 31 December 2024)
- IFN-Gamma Signaling in Cancer (Deadline: 31 December 2024)
- Macrophage-Directed Cancer Immunotherapy (Deadline: 31 December 2024)
- Immune Checkpoint Inhibitor-Based Immunotherapy in Cancer: Predictive Biomarkers and Mechanisms of Resistance (Deadline: 31 December 2024)
- CAR T Cells in Lymphoma and Multiple Myeloma (Deadline: 31 January 2025)
- Immunotherapy for Cancers (Deadline: 31 January 2025)
- Combination Immunotherapy for Cancer Treatment (Deadline: 10 February 2025)
- Advances and Challenges in the Treatment of HPV-Associated Lower Genital Tract Cancers by Immune Checkpoint Blockers: Insights from Basic and Clinical Science (Deadline: 25 February 2025)
- Monoclonal Antibodies in Lymphoma (Deadline: 28 February 2025)
- Cutting-Edge Innovations and Clinical Impact of CAR-Based Cancer Immunotherapy (Deadline: 28 February 2025)
- Immunotherapy with Checkpoint Inhibitors for Non-small Cell Lung Cancer (Deadline: 31 March 2025)
- Oncolytic Viruses as an Emerging Aspect of Immune Oncology (Deadline: 31 March 2025)
- Immunoediting in Cancer Therapies (Deadline: 13 April 2025)
- PD-1/PD-L1 Immune Checkpoint Therapy: From Predictive Biomarkers to Noninvasive Imaging 2nd Edition (Deadline: 25 April 2025)
- Evidence from the Real World Provides New Insights into the Evolving Landscape of Cancer Immunotherapy (Deadline: 30 April 2025)
- How to Properly Diagnose and Treat Immune-Related Adverse Events during Immunotherapy in Patients with Cancer: Discussion between Specialists (Deadline: 30 April 2025)
- Immunotherapy for Skin Cancers (Deadline: 1 May 2025)
- Identification and Clinical Application of Immunological Receptors Targeting Mutated Antigens Expressed by Solid Tumors (Volume II) (Deadline: 5 May 2025)
- Targeting Immune Checkpoints for Cancer Therapy: Potential and Challenges (Deadline: 10 May 2025)
- Cancer Immunotherapy: Focus on Immune Checkpoint Inhibitors and Immune Modulators (Deadline: 18 May 2025)
- Prostate Cancer and Inflammation (Deadline: 31 May 2025)
- New Insights in the Role of Myeloid-Derived Suppressor Cells (MDSCs) in Cancer (Deadline: 31 May 2025)
- Immune-Related Adverse Events in Cancer Immunotherapy (Deadline: 30 June 2025)
- Updates on Immune Checkpoint Inhibitors in Hepatocellular Carcinoma (Deadline: 30 June 2025)
- Immunotherapy Approaches in Breast Cancer Treatment (Deadline: 30 June 2025)
- CAR T Therapy of Solid Cancers: Problems and Progress (Deadline: 30 June 2025)
- Recent Advances in Nanomedicine-Based Cancer Immunotherapy (Deadline: 30 June 2025)
- Immune Microenvironment and Immunotherapy in Malignant Brain Tumors (Deadline: 25 July 2025)
- Cancer and Immunomediated Inflammatory Diseases (IMIDs) (Deadline: 31 July 2025)
- Inflammation, Immunity, and Cancer Progression: 2nd Edition (Deadline: 1 August 2025)
- Immunotherapy of Glioblastoma (Deadline: 16 August 2025)
- Immunomodulation in Cancer Treatment (Deadline: 31 August 2025)
- CAR T-Cell Therapy and Multiple Myeloma (Deadline: 31 August 2025)
- Immunotherapy in Melanoma: Recent Advances and Future Directions (2nd Edition) (Deadline: 31 August 2025)
- Advances in T-Cell Immunotherapy for Acute Myeloid Leukemia (Deadline: 15 September 2025)
- Research Progress of Cutaneous Squamous and Basal Cell Carcinomas (Volume II) (Deadline: 20 September 2025)
- Immunotherapy of Non-Small Cell Lung Cancer (Deadline: 20 September 2025)
- Merkel Cell Carcinoma: From Molecular Mechanisms to Clinical Therapy—a Selection of Papers from the 8th Nordic/1st European MCC Meeting (Deadline: 30 September 2025)
- Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplantation (HCT) (Deadline: 30 September 2025)
- The Tumor Microenvironment and Molecular Aberrations Convey Immune Evasion (Volume II) (Deadline: 30 September 2025)
- Exploring Immunotherapy in Colorectal Cancer (Deadline: 1 October 2025)
- Near-Infrared Photoimmunotherapy for Cancer Treatment: 2nd Edition (Deadline: 10 October 2025)
- Cancer Immunotherapy as Part of Precision Clinical Medicine (Deadline: 30 October 2025)
- Cancer Inhibitory Receptors and Related Cancer Immunotherapy (Deadline: 31 October 2025)
- Neuro-Immune Orchestration in Brain Tumors: From Molecular Signatures to Therapeutic Innovation (Deadline: 1 November 2025)
- Immune Landscape of Renal Cell Carcinoma (Deadline: 30 November 2025)
- Immunotherapy in the Management of Hematologic Malignancy (Deadline: 30 November 2025)
Topical Collections
Following topical collections within this section are currently open for submissions:
